Thursday, 2 July 2026 edition — The Vital Record
Vol. 1 · No. 30
Thursday, 2 July 2026
“Evidence first, then clarity.”
In this edition
Today's edition leads with FDA's historic June 30 approval of Tregzi — the first regulatory T-cell immunotherapy ever cleared anywhere — which cut chronic graft-versus-host disease risk by more than half in the randomized PRECISION-T trial; the issue pairs that regulatory milestone with two companion Nature papers reporting the first proof-of-concept that germline-targeting HIV vaccines can elicit broadly neutralizing antibodies in outbred primates, a molecular landmark four decades in the making.
Trials Today
Phase 3
ADEPT-5 (NCT06947941)
— BMS KarXT (Cobenfy) for psychosis in Alzheimer's disease; 325 participants, recruiting since March 2026; primary endpoint NPI-C hallucinations-plus-delusions score change at Week 14
Phase 3
ADAGIO-1 (NCT07011732)
— BMS KarXT (Cobenfy) for agitation in Alzheimer's disease; 426 participants, recruiting since July 2025
Phase 2/3
Etrasimod Crohn's (NCT04173273)
— Pfizer seamless adaptive trial, 379 enrolled across 510 sites; TERMINATED — results submitted to registry; no termination reason listed
Phase 3
HERO / ARD-101 (NCT06828861)
— Aardvark Therapeutics ARD-101 for Prader-Willi syndrome hyperphagia; TERMINATED — both pivotal RCT and open-label extension (NCT07197034) closed simultaneously
Phase 3
ARTEMIS (NCT05746559)
— Alexion/AstraZeneca ravulizumab (Ultomiris) for cardiac surgery-associated AKI in CKD patients; 544 enrolled, completed May 2026; no results posted
Phase 3
OTAC / INSIGHT-012 (NCT04910269)
— NIH/NIAID-funded hyperimmune IVIG for high-risk COVID-19 outpatients; 820 enrolled; SUSPENDED — reason not stated in registry
Who's Who
Robert Michael
Chief Executive Officer, AbbVie
Announced AbbVie's $10.9 billion all-cash acquisition of Apogee Therapeutics on June 22, 2026, adding zumilokibart (APG777), an IL-13–targeting monoclonal antibody in late-stage development for atopic dermatitis and asthma, to AbbVie's immunology pipeline as it braces for Humira biosimilar headwinds.
The story →
The Daily Record
Medicine & biotech, fully cited, in your inbox each morning.
Free. Unsubscribe anytime.
← The archive